Download PDF
Thromb Haemost 1994; 71(03): 305-313
DOI: 10.1055/s-0038-1642435
Original Article
Schattauer GmbH Stuttgart

Pharmacokinetics and Pharmacodynamics of a Low Molecular Weight Heparin (Enoxaparin) after Subcutaneous Injection, Comparison with Unfractionated Heparin – A Three Way Cross Over Study in Human Volunteers

Ana Victoria Bendetowicz
The Department of Biochemistry, Cardiovascular Research Institute Maastricht, University of Limburg, Maastricht, The Netherlands
,
Suzette Béguin
The Department of Biochemistry, Cardiovascular Research Institute Maastricht, University of Limburg, Maastricht, The Netherlands
,
H Caplain
1   Institut Aster, Paris, France
,
H Coenraad Hemker
The Department of Biochemistry, Cardiovascular Research Institute Maastricht, University of Limburg, Maastricht, The Netherlands
› Author Affiliations
Further Information

Publication History

Received: 17 June 1993

Accepted after revision 15 September 1993

Publication Date:
06 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

We determined, in volunteers, the plasma levels of heparin above and below the critical chainlength necessary for thrombin inhibition (ACLM and BCLM), from 1 to 24 h after subcutaneous injection of 5000IU unfractionated heparin (UFH), 40 mg enoxaparin and 1 mg/kg body weight of enoxaparin (LMWH) (n = 12 for each dose). The levels were calculated from the antithrombin- and anti-Xa activities using the specific activities of the materials injected. We also determined the course of thrombin- and of factor Xa generation after triggering the extrinsic system in the same samples. From the thrombin generation curves, we calculated the course of prothrombinase activity.

When the ACLM and BCLM plasma-levels are plotted against the inhibition of thrombin- and factor Xa generation, it appears that:

a) There is a unique dose response relationship between ACLM level and the inhibition of thrombin generation, independent of whether the ACLM is derived from UFH or LMWH. This relationship is not significantly altered by the BCLM appearing after LMWH injection.

b) There is a similar unique relationship between ACLM level and the inhibition of factor Xa generation, again independent of BCLM.

c) Inhibition of prothrombin activation hardly contributes to the overall effect on thrombin formation and is again independent of the source of ACLM.

d) ACLM levels were significantly higher after injection of LMWH than after UFH injection, even though the amounts of ACLM injected with the highest dose of LMWH were smaller than those administered in the UFH injection.

We conclude that the only functional difference between LMWH and UFH is the much higher bioavailability of the former. We surmise that, from the UFH injected, only the lower molecular weight species reach the circulation, i. e. a fraction similar to the ACLM injected with enoxaparin.

 

  • References

  • 1 Johnson EA, Kirkwood TBL, Striding Y, Perez-Requejo JL, Ingram GIC, Bangham DR, Brozovic M. Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous injection. Thromb Haemost 1976; 35: 586-91
    Thieme ConnectPubMedSearch in Google Scholar
  • 2 Yin ET, Wessler S, Stoll PJ. Biological properties of the naturally occurring inhibitor to activated factor X. J Biol Chem 1971; 246: 3703-11
    PubMedSearch in Google Scholar
  • 3 Hemker HC, Béguin S, Bendetowicz AV, Wielders S. The determination of the levels of unfractionated heparin and low molecular weight heparins in plasma. Their effect on thrombin mediated feedback reactions in vivo. Preliminary results on samples after subcutaneous injection. Haemostasis 1991; 21 (04) 258-72
    PubMedSearch in Google Scholar
  • 4 Bendetowicz AV, Pacaud E, Béguin S, Uzan A, Hemker HC. On the relationship between molecular mass and anticoagulant activity of a low-molecular weight heparin (enoxaparin). Thromb Haemost 1992; 67: 556-62
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 Béguin S, Wielders S, Lormeau JC, Hemker HC. The mode of action of CY 216 and CY 222 in plasma. Thromb Haemost 1992; 67: 33-41
    Thieme ConnectPubMedSearch in Google Scholar
  • 6 Béguin S, Kessels H, Dol F, Hemker HC. The consumption of Antithrombin III during coagulation, its consequences for the calculation of prothrombinase activity and the standardisation of heparin activity. Thromb Haemost 1992; 68: 136-12
    Thieme ConnectPubMedSearch in Google Scholar
  • 7 Hemker HC, Willems GM, Béguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemostas 1986; 56: 9-17
    PubMedSearch in Google Scholar
  • 8 Béguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 1988; 60: 457-62
    Thieme ConnectPubMedSearch in Google Scholar
  • 9 Owren PA, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand J Clin Lab Invest 1951; 3: 201-18
    CrossrefPubMedSearch in Google Scholar
  • 10 Josso F, Prou-Wartelle O. Exploration de 1/hemostase In: Techniques en Hematologie. Alagille D. edts. Flammarion; Paris: 1972: 101-8
  • 11 Lindhout T, Govers-Riemslag JWP, der Waart PVan, Hemker HC, Rosing J. Factor Va - Factor Xa interaction. Effect of phospholipid vesicles of different composition. Biochemistry 1982; 21: 5494-502
    CrossrefPubMedSearch in Google Scholar
  • 12 Pieters J, Lindhout T, Hemker HC. In situ generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin activated plasma. Blood 1989; 1021-4
    PubMedSearch in Google Scholar
  • 13 Schoen P, Hemker HC, Lindhout T. Ratios of anti-factor Xa to anti-thrombin activities in recalcified human plasma. Brit J Haemat 1992; 81: 255-62
    CrossrefPubMedSearch in Google Scholar
  • 14 Hemker HC, Wielders S, Kessels H, Béguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-24
    Thieme ConnectPubMedSearch in Google Scholar
  • 15 Béguin S, Mardiguian J, Lindhout T, Hemker HC. The Mode of Action of Low Molecular Weight Heparin Preparation (PK 10169) and Two of its Major Components on Thrombin Generation in Plasma. Thromb Haemost 1989; 61 (01) 30-4
    Thieme ConnectPubMedSearch in Google Scholar
  • 16 Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17
    PubMedSearch in Google Scholar
  • 17 Danishefsky I, Eiber HB. Studies on the metabolism of heparin. Arch Biochem Biophys 1959; 85: 53-61
    CrossrefPubMedSearch in Google Scholar
  • 18 Shanberge JN, Gruhl M, Kitani T, Ambegaonkar S, Kambayashi J, Nakagawa M, Lenter D. Fractionated tritium labelled heparin studies in vitro and in vivo. Thromb Res 1978; 13: 767-83
    CrossrefPubMedSearch in Google Scholar
  • 19 Dawes J, Pepper DS. Catabolism of low dose heparin in man. Thromb Res 1979; 14: 845-60
    CrossrefPubMedSearch in Google Scholar
  • 20 Dawes J, Prowse CV, Pepper DSHeparin. LMW heparin and SP54 concentrations after subcutaneous injection. Thromb Res 1986; 44: 683-93
    CrossrefPubMedSearch in Google Scholar
  • 21 Boneu B, Caranobe C, Sie P. Pharmacokinetics of heparin and low molecular weight heparin. Balliere’s Clinical Haematology 1990; 3: 531-44
    PubMedSearch in Google Scholar
  • 22 Frydman AM, Bara L, Roux YLe, Woler M, Chauliac F, Samama MM. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharm 1988; 28: 609-18
    CrossrefPubMedSearch in Google Scholar
  • 23 Thomas DP, Merton RE. A low molecular weight heparin compared with unfractionated heparin. Thromb Res 1982; 28: 343-50
    CrossrefPubMedSearch in Google Scholar
  • 24 Bratt G, Tornebohm E, Lockner D, Bergstrom K. A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment. Thromb Haemost 1985; 53: 208-11
    Thieme ConnectPubMedSearch in Google Scholar
  • 25 Bratt G, Tornebohm W, Widlund L, Lockner D. Low molecular weight heparin (KABI2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986; 42: 613-9
    CrossrefPubMedSearch in Google Scholar
  • 26 Dawes J, Bara L, Roux YLe, Woler M, Chauliac F, Samama MM. The anti thrombotic activity and concentration of a low-molecular-weight-heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostasis 1986; 16: 116-22
    PubMedSearch in Google Scholar
  • 27 Matzsch T, Bergqvist D, Hedner U, Gstergaard P. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thrombosis and Haemostasis 1987; 17: 97-101
    PubMedSearch in Google Scholar
  • 28 Dryjski M, Schneider DE, Mojaverian P, Be-Sheng Kuo, Bjomsson TD. Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations. British J Clin Pharm 1989; 28: 188-92
    PubMedSearch in Google Scholar
  • 29 Barrowcliffe TW, Johnson EA, Thomas DP. Low molecular weight heparin. John Wiley & Sons; Chichester: etc 1992
    Search in Google Scholar
  • 30 Hemker HC. The mode of action of heparin in plasma. In: Thrombosis and Haemostasis Verstraete M, Vermylen J, Lijnen HR, Amout J. Eds. I. S. T. H. Leuven University Press; 1987: 17-36
    Search in Google Scholar
  • 31 Barrowcliffe TW, Havercroft SJ, Kemball-Cook G, Lindahl U. The effect of Ca2+, phospholipid and factor V on the anti (Factor Xa) activity of heparin and its high-affinity oligosaccharides. Biochem J 1987; 243: 31-7
    CrossrefPubMedSearch in Google Scholar
  • 32 Ellis V, Scully MF, Kakkar VV. The acceleration of the inhibition of plate let prothrombinase complex by heparin. Biochemical Journal 1986; 233: 161-5
    CrossrefPubMedSearch in Google Scholar
  • 33 Schoen P, Lindhout T, Willems G, Hemker HC. Antithrombin III Dependent Anti-Prothrombinase Activity of Heparins of Various Molecular Weight. J Biol Chem 1989; 264 (17) 10002-7
    PubMedSearch in Google Scholar
  • 34 Sandset P, Abilgaard U, Larsen AL. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-13
    CrossrefPubMedSearch in Google Scholar
  • 35 Lindahl AK, Abilgaard U, Larsen ML, Aamodt LM, Nordfang P, Beck TC. Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation. Thromb Res 1991; Suppl XIV: 39-48
    PubMedSearch in Google Scholar
  • 36 Béguin S, Lindhout T, Hemker HC. The effect of trace amounts of thromboplastin on the generation of thrombin in platelet rich plasma, its inhibition by heparin. Thrombosis and Haemostasis 1989; 61: 25-9
    Thieme ConnectPubMedSearch in Google Scholar